SPINOVIT is a spin off from UCLouvain offering a solution to detect the earliest stages of a cardiovascular disease. The assessment of a robust biomarker of endothelial dysfunction allows the identification of the personal risk of a patient and so the prevention of the development of a cardiovascular disease.
SPINOVIT developed an original method to assess the endothelial dysfunction by measuring a biomarker in a 1 mL blood sample. Our solution consists in a patented syringe and measurement of a biomarker by an innovative technology. This biomarker reveals the quantity of nitric oxide (NO) produced by the endothelial cells. As this production is modulated by the risk factors, our biomarker can so provide information on the real risk exposure of a patient allowing so a personalized medicine approach.
This procedure ensures a safe, minimally invasive and cost-effective method for the patient and an easy, reproducible, evidence-based assessment with an incremental value over standard for the physician.